Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 427-820-5 | CAS number: 2701-50-0 1,2-METHYLEN-4,6-DIENACETAT
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- April to May 1998
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study without detailed documentation
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 998
- Report date:
- 1998
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Version / remarks:
- 1995-07-27
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- 17-acetoxy-1β,2β-methanopegna-4,6-diene-3,20-dione
- EC Number:
- 427-820-5
- EC Name:
- 17-acetoxy-1β,2β-methanopegna-4,6-diene-3,20-dione
- Cas Number:
- 2701-50-0
- Molecular formula:
- C24H30O4
- IUPAC Name:
- (1S,2S,3R,5S,11R,12S,15R,16S)-15-acetyl-2,16-dimethyl-6-oxopentacyclo[9.7.0.0²,⁸.0³,⁵.0¹²,¹⁶]octadeca-7,9-dien-15-yl acetate
- Test material form:
- solid: bulk
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Strain: HAN: WIST (SPF)
- Source: Schering AG
- Age at study initiation: not reported
- Weight at study initiation: males 186-221 g, females 167-193 g
- Housing: singly in conventional housing conditions (Makrolon type III cages)
- Diet and water: ad libitum
- Acclimation period: 7 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21-23
- Humidity (%): 46-70
- Air changes (per hr): not reported
- Photoperiod (hrs dark / hrs light): 12/12
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- other: 0.9 % NaCl + 0.085 Myrj 53
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The content of the test substance in the formulation was analytically verified for all doses at least at beginning and termination of the study.
Method of analysis: HPLC with UV absorption following appropriate dissolution and dilution with mobile phase appropriately. - Duration of treatment / exposure:
- 4 weeks
- Frequency of treatment:
- once daily
Doses / concentrations
- Remarks:
- Doses:
0, 40, 200, 1000 mg/kg in an application volume of 10 ml/kg
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent vehicle
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes, all animals
All signs of weak health, reactions to treatment and behavioural changes were recorded.
- Time schedule: Animals were checked regularly twice daily, also on weekends.
BODY WEIGHT: Yes, all animals
- Time schedule for examinations: once weekly
FOOD CONSUMPTION:
- Time schedule for examinations: once weekly
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
WATER CONSUMPTION: Yes, all animals
- Time schedule for examinations: once weekly
OPHTHALMOSCOPIC EXAMINATION: Yes, all animals
- Time schedule for examinations: week 4
HAEMATOLOGY:
- Time schedule for collection of blood: Day 28
- Anaesthetic used for blood collection: No data
- Animals fasted: not specified
- Parameters checked: Hematological investigations including determination of the following parameters were performed on Day 24: erythrocyte and leucocyte count, hemoglobin, hematocrit (packed cell volume), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), mean corpuscular volume (MCV), reticulocyte count, platelets, and differential count [neutrophils (myelocytes, immature, band types l and II, segmented), Iymphocytes, eosinophils, basophils, monocytes].
CLINICAL CHEMISTRY: Yes, all animals
- Time schedule for collection of serum: Day 2 and Day 28
- Parameters checked: alanine aminotransferase (ALT) and alkaline phosphatase (ALP) on Day 2 (approximately 24 hours after the first treatment) and Day 28,
total cholesterol, glucose, urea nitrogen, total protein, protein electrophoresis, sodium, potassium, calcium and chloride on Day 28 only.
URINALYSIS: Yes, all animals
- Time schedule for collection of urine: Day 25
- Parameters checked: pH, specific gravity and volume as weil as protein, glucose, blood, ketones, urobilinogen, bilirubin and sediment of urine.
NEUROBEHAVIOURAL EXAMINATION: Yes
On days -6 or -5 and 22 the following neurological examinations were performed in all rats
a) brain reflexes:
pupillary light reflex, eonsensuallight reflex, palpebral reflex and corneal reflex
b) spinal reflexes:
flexor withdrawl reflex.
e) postural and attitudinal reactions:
placing reaction, righting reaction, balancing test and grasping reflex
d) sensitivity test:
sensitivity of skin (torso) and head shaking reaction - Statistics:
- The Dunnett-test was used to assess the statistical significance of differences between the control and the treatment groups.
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, non-treatment-related
- Description (incidence and severity):
- The observed findings such as hairless areas, thinning of fur, scab formations at several locations and hematomas at the external ear were not considered to be compound-related, because they were sporadically seen in only one animal each and are known sporadic findings due to traumata.
- Mortality:
- mortality observed, non-treatment-related
- Description (incidence):
- The animal nos.: 13F, 15F and 53F died on day 2 of the study due to the blood
sampling procedure.
Animal no. 31 F died on day 28 also accidentally after blood sampling. - Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Ophthalmological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- The findings such as vesicular inclusions at the cornea and bloodfilled vessels across the vitreous body were not considered to be compound-related because they were observed sporadically in single animals of groups 2 and 4 (40 and 1000 mg/kg) without dose-dependence.
- Haematological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Decrease in MCV and hematocrit not condered to be compound-related due to lack of dose-dependency.
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- The following suspected compound-related effects were observed on day 28 of the study:
- slight increase in total protein in female animals ofgroup 4 (p < 0.05);
- increase in glucose in female animals of group 4 (p < 0.01).
None of the other statistically significant differences to the control group were considered to be compound-related. - Urinalysis findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- None of the findings observed in urine, such as protein, blood, ketones, urobilinogen and bilirubin as well as urinary sediment findings were considered to be compound-related,
because of the lack of a dose dependence or they were also seen in control animals or occurred only sporadically. - Histopathological findings: non-neoplastic:
- effects observed, non-treatment-related
- Description (incidence and severity):
- None of the findings which were observed at the histopathological examination was regarded
as being compound-related because they ocurred at comparable incidence in contra I and
treatment goups or they occurred only sporadically or they were known spontaneaus findings in the used strain of rats. - Other effects:
- effects observed, treatment-related
- Description (incidence and severity):
- Coagulation:
The only suspected compound-related effect was a statistically significant slight decrease (p < 0.05) in fibrinogen observed in female animals of group 4 on day 29.
Effect levels
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- behaviour (functional findings)
- body weight and weight gain
- clinical biochemistry
- clinical signs
- food consumption and compound intake
- gross pathology
- haematology
- histopathology: non-neoplastic
- mortality
- neuropathology
- ophthalmological examination
- organ weights and organ / body weight ratios
- serum/plasma biochemistry
- urinalysis
- water consumption and compound intake
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
The repeated intragastric administration of ZK 5690 at doses of 40, 200 and 1000 mg/kg to male and female rats over aperiod of 4 weeks was tolerated without general or organ toxicity.
The increase in glucose in females of graup 4 is only suspected as being compound-related although a clear difference to the control animals was noted. However, the glucose values of the treated animals remained well within the reference range whereas the respective values of the control group were in the lower range of the reference values. Therefore, this finding is
regarded as being of minor biological significance.
The slight decrease in fibrinogen in females of group 4 was suspected to be treatment-related but was regarded as being of minor toxicological relevance. The value remained within the historical reference value range, i.e. within the normal biological variability and the difference of the value between the high-dose group and the control group was too slight to be of biological significance. The increase in organ weight of the liver in female animals of dose group 4, which correlates with the slight increase in total protein in the same group, is regarded to be related to an adaptation to the high metabolic loading of the liver.
Applicant's summary and conclusion
- Conclusions:
- The daily intragastric administration of ZK 5690 at dose levels of 40, 200 and 1000 mg/kg to male and female rats over a treatment period of 4 weeks was tolerated without relevant toxic effects. At the high dose, signs of an adaptation to the high metabolite loading of the liver occurred in female rats, but no indications of general or organ toxicity were found in either gender.
- Executive summary:
Three groups of 10 M/10 F rats (Han: WIST) each received daily intragastric administrations of 40, 200 and 1000 mg ZK 5690/kg, respectively, at a volume of 10 ml/kg over aperiod of ca. 4 weeks (28-31 applications). Another group of 10 M/10 F received the vehicle at the same volume and served as control.
The effects of ZK 5690 were evaluated using clinical, biochemical and hematological parameters as well as bane marrow examination, urinalysis, organ weight analysis and pathological macroscopic and microscopic examination.
For statistical evaluation, the Dunnett-test was used.
No compound-related effect was observed after the low and mid doses of 40 and 200 mg ZK 5690/kg.The following suspected compound-related effects were observed after the high dose of 1000 mg/kg in females:
- slight increase (p < 0.05) in total protein in females;
- increase (p < 0.01) in glucose in females;
- slight decrease (p < 0.05) in fibrinogen in females;
- increase in absolute (p< 0.05) and relative (p < 0.01) organ weight of the liver in female animals.
Of the above-mentioned findings the slight increase in total protein accompanied by an increase of liver weight in females of group 4 is regarded as indication of metabolic activation of the liver. The slight decrease in fibrinogen as well as the increase in glucose were regarded as minor changes because the values remained within the reference range. Therefore, it was not regarded as being of biological significance.Therefore, the NOAEL can be regarded to be 1000 mg/kg/day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.